SCHEMBL1049280

SCHEMBL1049280

COc1ccc(-c2cnc(Nc3ccccc3)c3c(=O)[nH]ccc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
ZAP70 P43403 2/20 0.48
TTBK1 Q5TCY1 2/20 0.46
TTBK2 Q6IQ55 2/20 0.46
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FGFR1 P11362 1/20 0.44
SRC P12931 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GSK3B P49841 1/20 0.43
BTK Q06187 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
BRAF P15056 2/20 0.42
DYRK1A Q13627 1/20 0.42
DYRK1B Q9Y463 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049635 0.89 ZAP70 (0.53) MAPTZAP70TTBK1TTBK2FGFR1
SCHEMBL1050006 0.89 BTK (0.56) MAPTLMNAZAP70TTBK1TTBK2
SCHEMBL1048999 0.86 ZAP70 (0.49) MAPTZAP70TTBK1TTBK2GSK3B
SCHEMBL1047395 0.85 ZAP70 (0.48) MAPTLMNAZAP70TTBK1TTBK2
SCHEMBL1048942 0.85 ZAP70 (0.48) MAPTLMNAZAP70TTBK1TTBK2
SCHEMBL1043299 0.85 JAK2 (0.49) MAPTZAP70TTBK1TTBK2GAA
SCHEMBL1044222 0.83 LMNA (0.51) MAPTLMNAZAP70TTBK1TTBK2
SCHEMBL1047746 0.83 ZAP70 (0.46) ZAP70TTBK1TTBK2GSK3B
SCHEMBL1048920 0.82 CDC7 (0.53) ZAP70TTBK1TTBK2GSK3BBRAF
SCHEMBL1045599 0.81 ZAP70 (0.47) ZAP70TTBK1TTBK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET MAPT 3127/4885LMNA 2865/4885ZAP70 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.